Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10813052 | 0.80 | CYP1A2 (0.59) | CYP1A2KDM4E | |
| SCHEMBL17753581 | 0.80 | TNKS (0.34) | PARP1CYP1A2 | |
| SCHEMBL9838320 | 0.73 | KDM4E (0.58) | KDM4E | |
| SCHEMBL1869453 | 0.68 | HCAR2 (0.66) | PARP1 | |
| SCHEMBL12235160 | 0.67 | KDM4E (0.50) | CYP1A2KDM4EAURKA | |
| SCHEMBL24659326 | 0.67 | SMN1; SMN2 (0.60) | PARP1CYP1A2KDM4EAURKA | |
| SCHEMBL31138368 | 0.65 | KDM4E (0.39) | PARP1CYP1A2KDM4ECCR1CCR5 | |
| SCHEMBL3256923 | 0.62 | HTT (0.40) | PARP1KDM4EAURKA | |
| SCHEMBL13686508 | 0.62 | DHFR (0.43) | KDM4E | |
| SCHEMBL15785416 | 0.62 | PARP1 (0.37) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364482-B2 | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20160136172-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2016-05-19 | — | — | US | disclosed |
| WO-2014205593-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014209727-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136172-A1 | SUBSTITUTED BENZOFURAN COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | GTF3C5, HCCS, EIF2AK2 | PARP1 1344/4885CYP1A2 332/4885KDM4E 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.